What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2443.png

ad-02.png

SCEMBLIX is a NOVEL STAMP inhibitor with a different mechanism of action specifically targeting the ABL myristoyl pocket1

 

Scemblix MOA Video VIDEO

 

Dive In: See what’s new

 

  • SCEMBLIX targets a specific site on BCR::ABL1 - the myristoyl pocket.2

  • The myristoyl pocket is a distinct site of the kinase domain, normally occupied by the myristoylated N-terminal of ABL1 in people who do not have CML.3

  • By binding to the myristoyl pocket, SCEMBLIX allows for specificity in treating CML – targeting BCR :: ABL14

 

Group 2370.png

A different way to treat CML: Scemblix

Scemblix is a new treatment for later lines of CML1, and it's the first in class approved treatment of its kind.2

Group 2365.png
Group 2366.png

It's a STAMP inhibitor meaning it specifically targets the ABL1 Myristoyl Pocket.2

Scemblix specifically targets ABL1 in the Myristoyl pocket, which is distinct from the ATP binding site.5

Group 2367.png
Group 2368.png

When Scemblix binds to the Myristoyl pocket, it acts as the missing part of the kinase and inhibits the activity of BCR-ABL1.1
Scemblix allows for specificity in treating CML, by targeting and binding to ABL1 over hundreds of other targets.1

Approach CML differently with Scemblix2, the first in class approved STAMP inhibitor specifically targeting the ABL1 Myristoyl pocket and CML.1

Group 2369.png

CML, chronic myeloid leukemia; ABL 1, Abelson protein tyrosine kinase 1; TKI, Tyrosine Kinase Inhibitor; BCR, breakpoint cluster region; IS, International Scale; STAMP, specifically targeting the ABL1 myristoyl pocket; MMR, Major molecular response; MR4, BCR::ABL1IS 0.01% 

For Scemblix 20mg and 40mg Abbreviated Prescription Information

PDF
View

References

  1. Food and Drug administration (FDA). Scemblix MULTI-DISCIPLINE REVIEW. available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215358Orig1s000,Orig2s000MultidisciplineR.pdf . Last accessed 16/6/2025 

  2. Choi EJ. Asciminib: the first-in-class allosteric inhibitor of BCR:: ABL1 kinase. Blood research. 2023 Apr 30;58(S1):S29-36. 

  3. Scemblix Egyptian Drug Authority (EDA) Approved leaflet 05/05/2025. 

  4. Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood, The Journal of the American Society of Hematology. 2021 Nov 25;138(21):2031-41. 

  5. Réa D, Hughes TP. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. Critical Reviews in Oncology/Hematology. 2022 Mar 1;171:103580. 

Approved by Egyptian Drug Authority: HF0424OA4707/092025. Invalidation date: 18/09/2027.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at:
www.edaegypt.gov.eg

Scemblix QR Code

HF0424OA4707/092025
18/09/2027

 

        

Adverse Events Reporting

We encourage using the following Electronic reporting tool for reporting into the safety database directly:
If the electronic reporting tool is not working - please use the following: https://www.report.novartis.com
1 - Generic Mailbox: [email protected]
2 - CISCO: +20 2 2 2861000: Press 3 for Adverse Events Reporting